Posttransplant lymphoproliferative disorders following hematopoietic stem cell transplantation: a clinicopathological study of a large single-center cohort.
5 affiliations
- 1Pathology Center, Shanghai Genenal Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200080, China.
- 2Department of Pathology, Bengbu Hospital of Shanghai Genenal Hospital/The Second Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, 233000, China.
- 3Department of Pathology, Shanghai Eighth People's Hospital, Shanghai, 200235, China.
- 4Department of Hematology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200080, China.
- 5Cancer Center, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, No.100 Hai Ning Road, Hong'kou District, Shanghai, 200080, China. [email protected].
Abstract
Posttransplant lymphoproliferative disorder (PTLD) is a serious complication of hematopoietic stem cell transplantation (HSCT) and is typically driven by immunosuppression and Epstein-Barr virus infection. This study analyzed the clinicopathological spectrum and outcomes of PTLD in a large single-center cohort. We retrospectively reviewed 37 PTLD patients who were diagnosed post-HSCT (2017-2024). Histopathological classification was conducted in accordance with the 5th Edition of the World Health Organization Classification of Hematolymphoid Tumors (WHO-HAEM5). Immunohistochemistry, EBV-encoded RNA in situ hybridization, fluorescence in situ hybridization, and clonality assays were performed. Clinical data, treatment responses, and survival outcomes were collected and analyzed. The PTLD incidence was 2.4% among allo-HSCT recipients, with a male predominance (2.36:1). The median time to onset post-HSCT was 3 months (range: 1-21 months), with 81.1% of cases occurring within 6 months. The pathological types of PTLD included hyperplasias (9 cases), polymorphic PTLD (20 cases), and lymphoma (8 cases; all diffuse large B-cell lymphomas). First-line management include reduced immunosuppression, rituximab, and antiviral therapy. Prebiopsy rituximab in 5 patients caused CD20 loss, complicating the diagnosis. The mortality rate was 27%, primarily from infectious complications following PTLD-directed therapy. The median postdiagnosis survival was 3.5 months. PTLD post-HSCT is a serious complication that often follows an aggressive clinical course. While the direct contribution of PTLD to mortality was challenging to establish, its development frequently triggered intensive interventions (e.g., rituximab and immunosuppression reduction), which in turn led to fatal infectious complications in more than one-quarter of our cohort. Therefore, the high mortality in these patients was largely indirect and attributable to treatment-related infectious complications in profoundly immunocompromised hosts.
Related
- Molecular profiling and disease tracking of posttransplant lymphoproliferative disorders using cell-free DNA∗
- Unravelling the biological divergence of CD30+ lymphoproliferative disorders with skin involvement: from clinical risk to precision oncology
- Age, Comorbidity Burden and Treatment Outcomes in Mature B-Cell Lymphoproliferative Disorders: A Real-World Study.
- The role of allogeneic hematopoietic stem cell transplantation in adults with mature T‐cell lymphomas
- A randomized controlled trial of a multidisciplinary collaborative fatigue management program for patients undergoing hematopoietic stem cell transplantation: study protocol
BibTeX
@article{lin2026posttransplant,
title = {{Posttransplant lymphoproliferative disorders following hematopoietic stem cell transplantation: a clinicopathological study of a large single-center cohort.}},
author = {Jun Lin and Mengyun Zhou and Chang Shen and Feng Peng and Cheng Xu and Qian Huang},
journal = {Annals of hematology},
year = {2026},
month = aug,
doi = {10.1007/s00277-026-07225-4},
url = {https://europepmc.org/article/MED/42967967},
note = {CC BY},
}
RIS
TY - JOUR
TI - Posttransplant lymphoproliferative disorders following hematopoietic stem cell transplantation: a clinicopathological study of a large single-center cohort.
AU - Jun Lin
AU - Mengyun Zhou
AU - Chang Shen
AU - Feng Peng
AU - Cheng Xu
AU - Qian Huang
PY - 2026
DA - 2026/08/01
JO - Annals of hematology
DO - 10.1007/s00277-026-07225-4
UR - https://europepmc.org/article/MED/42967967
AB - Posttransplant lymphoproliferative disorder (PTLD) is a serious complication of hematopoietic stem cell transplantation (HSCT) and is typically driven by immunosuppression and Epstein-Barr virus infection. This study analyzed the clinicopathological spectrum and outcomes of PTLD in a large single-center cohort. We retrospectively reviewed 37 PTLD patients who were diagnosed post-HSCT (2017-2024). Histopathological classification was conducted in accordance with the 5th Edition of the World Health Organization Classification of Hematolymphoid Tumors (WHO-HAEM5). Immunohistochemistry, EBV-encoded RNA in situ hybridization, fluorescence in situ hybridization, and clonality assays were performed. Clinical data, treatment responses, and survival outcomes were collected and analyzed. The PTLD incidence was 2.4% among allo-HSCT recipients, with a male predominance (2.36:1). The median time to onset post-HSCT was 3 months (range: 1-21 months), with 81.1% of cases occurring within 6 months. The pathological types of PTLD included hyperplasias (9 cases), polymorphic PTLD (20 cases), and lymphoma (8 cases; all diffuse large B-cell lymphomas). First-line management include reduced immunosuppression, rituximab, and antiviral therapy. Prebiopsy rituximab in 5 patients caused CD20 loss, complicating the diagnosis. The mortality rate was 27%, primarily from infectious complications following PTLD-directed therapy. The median postdiagnosis survival was 3.5 months. PTLD post-HSCT is a serious complication that often follows an aggressive clinical course. While the direct contribution of PTLD to mortality was challenging to establish, its development frequently triggered intensive interventions (e.g., rituximab and immunosuppression reduction), which in turn led to fatal infectious complications in more than one-quarter of our cohort. Therefore, the high mortality in these patients was largely indirect and attributable to treatment-related infectious complications in profoundly immunocompromised hosts.
SN - 0939-5555
SN - 1432-0584
ER -